Drug and vaccine development for the treatment and prevention of urinary tract infections

Valerie P. O’Brien, Thomas J. Hannan, Hailyn V. Nielsen, Scott J. Hultgren

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations

Abstract

Urinary tract infections (UTI) are one of the most common bacterial infections, with roughly eleven-million cases reported in the U.S. each year that cost an estimated $5 billion annually (1, 2). More than one in every two women will experience at least one UTI in her lifetime, and nearly one in three women will have received antibiotic treatment for a UTI before age 24 (3, 4). The clinical manifestations of symptomatic UTI include infection-induced inflammation of the urethra (urethritis), urinary bladder (cystitis), and kidneys (pyelonephritis) and are diagnosed by the presence of high levels of bacteria in the urine (bacteriuria) with concomitant symptoms. Symptoms of cystitis include frequent urination, burning sensation and pain during urination (dysuria), suprapubic pain and/or lower abdominal discomfort, and cloudy and/or bloody, foul-smelling urine. Symptoms of pyelonephritis include the presence of bacteriuria and pyuria (white blood cells in the urine) that is accompanied by flank pain and fever, but may or may not include other symptoms of cystitis. The vast majority of UTI manifest as cystitis and urethritis, affecting primarily the lower urinary tract, but this can potentially lead to bacterial ascension to the kidneys and pyelonephritis, particularly in pregnant women, diabetics, and children with vesicoureteral reflux (VUR) (5, 6). As a result, renal scarring and loss of function is a potentially serious complication of any UTI, particularly in infants, where diagnosis of UTI may be delayed.

Original languageEnglish
Title of host publicationUrinary Tract Infections
Subtitle of host publicationMolecular Pathogenesis and Clinical Management
Publisherwiley
Pages589-646
Number of pages58
ISBN (Electronic)9781683670650
ISBN (Print)9781555817398
DOIs
StatePublished - Apr 19 2016

Keywords

  • Anti-virulence therapy
  • Avirulent asymptomatic bacteriuria
  • Bladder-mucosal immune response
  • Enterococcus faecalis
  • Estrogen therapy
  • Nutraceutical
  • Upec adhesin
  • Urinary tract infection vaccine

Fingerprint

Dive into the research topics of 'Drug and vaccine development for the treatment and prevention of urinary tract infections'. Together they form a unique fingerprint.

Cite this